Alnylam Pharmaceuticals reported $-329357000 in Pre-Tax Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Acadia Pharmaceuticals ACAD:US USD -26415000 7.15M
Agios Pharmaceuticals AGIO:US USD -81747000 10.06M
Alnylam Pharmaceuticals ALNY:US USD -329357000 54.68M
Arrowhead Research ARWR:US USD -82157000 10.11M
Bluebird Bio BLUE:US USD -76513000 16.99M
Intercept Pharmaceuticals ICPT:US USD -104087000 83.77M
Mirati Therapeutics MRTX:US USD -173307000 3.14M
Neurocrine Biosciences NBIX:US USD 97.9M 121.2M
Ptc Therapeutics PTCT:US USD -127208000 21.49M
Regeneron Pharmaceuticals REGN:US USD 1.45B 140.6M
Regulus Therapeutics RGLS:US USD -7551000 293K
Sangamo Biosciences SGMO:US USD -53125000 10.03M
Sarepta Therapeutics SRPT:US USD -256418000 28.32M
Takeda 4502:JP JPY 64.55B 90.92B
Ultragenyx Pharmaceutical RARE:US USD -238819000 80.96M
Xencor XNCR:US USD -31671000 2.3M
YTE INCY:US USD 178.22M 131.36M